The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
if you look at how onco blot was created you look at how the FDA gave it a type of approval which is not an FDA approval but there's you know and I don't wanna get into the weeds on that stuff but basically it was approved quote-unquote only for patients presenting with metastatic cancer of it with an unknown primary because of its remarkable ability to create a differentiation around 27 different types of tissue
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.